BioVersys AG Plans to Launch IPO on SIX Swiss Exchange

BioVersys AG, a clinical-stage biopharmaceutical company, has announced its intention to go public on the SIX Swiss Exchange in the first quarter of 2025. The IPO aims to raise CHF 80 million to support the progression of its lead asset, BV100, through Phase 3 trials, targeting regulatory filings by 2027.

The funds will also back the ongoing Phase 2 development of alpibectir for tuberculosis. BioVersys has shown promising Phase 2 data for both assets, positioning itself to address major health concerns like antimicrobial resistance (AMR), a significant global challenge endorsed by the WHO.

Supported by GSK and the AMR Action Fund, the company believes there is potential for a sustainable commercial opportunity with incoming reimbursement schemes for antibiotics. BioVersys emphasizes its commitment to combating antibiotic resistance through innovation and collaboration.